Bionical Emas launches Expanded Access Program for JZP458 – a recombinant Erwinia Asparaginase

Bionical Emas, a global specialist Clinical Research Organization (CRO), has today
announced the launch of a U.S. Expanded Access Program for Jazz Pharmaceuticals’
investigational therapy JZP458 (asparaginase Erwinia chrysanthemi (recombinant))
for the treatment of adult and pediatric patients with Acute Lymphoblastic Leukemia
(ALL) or Lymphoblastic Lymphoma (LBL) following hypersensitivity or silent
inactivation to E. coli-derived asparaginases. JZP458 is currently under FDA review
for marketing authorization in the United States. The Expanded Access Program
(EAP) provides a mechanism to fulfill unsolicited physician requests in the U.S. and
support the special need of a patient

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...